Zynex, Inc.

recorded. I would now like to turn the conference over to Greg Kodacek from the Gilmartin Group. Please go ahead.

Thank you, Sarah, and good afternoon, everyone. Earlier today, Zynex released financial results for the fourth quarter of 2021. A copy of the press release is available on the company's website. Joining me on today's call are Thomas Songard, Chairman, President, and Chief Executive Officer, Dan Moorhead, Chief Financial Officer, Anna Lusak, Chief Operating Officer, and Donald Gregg, Vice President of Zynex Monitoring Solutions. Before we begin, I'd like to remind you that during this conference call, the company will make projections and forward-looking statements regarding future events. We encourage you to review the company's past and future filings with the SEC, including without limitation, the company's Form 10-K and subsequent Form 10-Qs, which identify the specific factors that may cause actual results or events to differ materially from those described in these forward-looking statements. These factors may include, without limitation, statements regarding product development, product potential, the regulatory environment, sales and marketing strategies, capital resources, or operating performance. With that, I will now turn the call over to Thomas.

Thanks, Craig, and good afternoon, everyone. Thank you for joining us today. We will be reviewing activities in both Cynics business divisions. ZMI, the division for pain management, and CMS, our monitoring solutions division. Over the last 12 months, we have continued to build a profitable company with diversified strategies and pathways that we believe will ultimately drive our top line growth in many years to come. The first quarter represented yet another record of revenue and net income Revenue of $40.4 million and net income of $8.9 million, respectively. Our $42.6 million cash position is very substantial relative to a company of our size and increased sequentially by $7.2 million, approximately 20%, just during the fourth quarter. We continue to see consistent orders with fourth quarter figures coming in. 8% higher than the same quarter last year, and an adjusted EBITDA of $13 million in the quarter. 2021 numbers cemented our financial health. Looking forward, we expect to experience a seventh straight year of profitability. I will now turn the call over to Anna, our COO, to speak to operations in our revenue-generating pain management division.